Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results of NEXAVAR as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation was Not Met

Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results of NEXAVAR as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation was Not Met

Submitted by admin on March 11, 2014 - 8:22am
Source: 
Bloomberg
News Tags: 
Bayer
ONYX Pharmaceuticals
Nexavar
liver cancer
Headline: 
Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results of NEXAVAR as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation was Not Met

Do Not Allow Advertisers to Use My Personal information